Introduction
Castleman's disease is a rare proliferative disorder of a benign nature characterized by hyperplasia of lymphoid follicles. 1, 2 The most frequent location of the CD is the chest (70%) although this pathology can theoretically affect any nodal station. 2 The abdomen is rarely affected by this pathology, abdominal localizations reported in the literature are: mesentery, retroperitoneum, pancreas, pelvis and rectum. 3 Diagnosis is difficult and the diagnostic certainty is obtained only by histological examination. For this disease there is no goldstandard treatment.
Case report
A 33-year old woman with a silent pathology history, was referred to us for weight loss (about 3 kg) and epigastric pain radiated to the right side and rear in the lumbar region. The abdominal examination did not reveal anything pathological. The blood tests did not show anything at the pathological level and the tumor markers were normal, as were the results of chest X-rays. The abdominal ultrasound detected the presence in the right epigastric region a hypoechogenic image, homogeneous, round, surrounded by a hyperechogenic capsule (max diameter 31 mm), compressing from behind the ICV, laterally the gallbladder and contracts with the head of the pancreas. Given the inconsistency in interpretation and in order to obtain more detailed information a CT scam of the abdomen was carried out and this confirmed the presence between aorta and ICV, at the level of the duodenal C knee, a formation of 3 cm oval with homogeneous enhancement similar to after injection of intravenous contrast medium and the radiologist suggested that it was a leiomioma of the duodenal wall. In history the patient had reported repeated episodes of herpetic infection localized in the lip. The detection of the anti-HHV-8 antibodies was successful because the patient had serum antibodies against the virus.
The patient then underwent surgery of the formation. In the operating field there was nothing pathological as regards the stomach and duodenum. However, in the retroperitoneal location, below the third duodenal portion, in the paracaval site, there was a found a smooth, ovular, taught-elastic formation (Figs. 1 and 2). No retroperitoneal adenopathy was detected.
The histological examination showed that the lymph node was a neo-formation and this allowed us to make a diagnosis of Castleman's disease with vascular ialino-positive immunohistochemical reaction for CD-20 CD-3, CD-138 and Ki-67 (Figs. 3 and 4) .
After a clinical course without complications, the patient was discharged and is currently in good health.
Discussion
Castleman's disease is a rare benign disorder first described by Castleman in 1954 in a group of patients with mediastinal lymphoadenopathy.
2,4
The Castleman's disease may grow in any area where lymphoid tissue is normally present but the most frequent is mediastinal (67%), 5 the abdomen is rarely affected by this pathology; abdominal localizations reported in the literature are: mesentery, retroperitoneum, pancreas, pelvis, rectum, however, being mesenteric and perinephric sites the most frequent in pelvis. 3 The retroperitoneal location of the CD is extremely rare presenting only 7% of cases, 6 usually at the left side. In the literature in fact the ratio between the right and left location is equal to 13:4. 7 In our case the CD was localized in the right paramediana site. Castleman's disease in the abdomen and pelvis is even rarer and should be distinguished from tuberculosis of the mesentery, lymphoma, accessory spleen, and other hypervascular lesions. From the radiological and clinical points of view, disseminated Castleman's disease may be indistinguishable from lymphoma.
Ultimately, ultrasound-guided aspiration biopsy of an enlarged lymph node or mass is recommended for histopathological diagnosis. The etiology is currently unknown but it is assumed that this disease could be a response to a chronic inflammatory process, 4 an amartomatoso process, 10 a state of immunodeficiency 11 or an immune disorder. 12 The Epstein-Barr Virus, Toxoplasma and
Mycobacterium tuberculosis have been considered to be involved in the genesis of some cases of variant PC CD.
2,12
Several studies in animal models and humans have focused attention on the role of IL-6 in activation of the differentiation of plasma cells, the proliferative processes of the lymphoid cells 13 and vascular endothelium and the onset of events involved in this systemic disease. 10 The Human Herpes Virus 8 (HHV-8) is the causative agent of Kaposi's sarcoma in immunosuppressed subjects, 14 this virus was also frequently found in HIVþ and patients suffering from CD 15 and so it is possible to affirm that it can play an important role in the pathogenesis of Kaposi's sarcoma as well as the multicentric form of CD. In our case, the patient had anti-HHV-8 and also had a history of numerous reported incidents of herpetic infection, which could further support the view that this virus might be somehow involved in the pathogenesis of CD. The hypothesis that the IL-6 may play an important role in the pathogenesis of CD is supported by the fact that the HHV-8 has a gene coding for a protein similar to IL-6 (VIL-6) 16 which could be responsible for the clinical-pathological anatomy typical of CD. Treatment of unicentric CD most of the times is based on resection, which offers the best chance for cure. 18 In the near future, new treatment protocols for CD, such as antiinterlukin-6 receptor antibody (tocilizumab) therapy, 19 will be applied.
Conclusion
CD must be included in the differential diagnosis of retroperitoneal tumors even though the definitive diagnosis can only be achieved by histological and immunohistochemical examination. The retroperitoneal location is rare, especially if the lesion is located on the right. In the pathogenesis of CD an important role could be played by HHV-8 whose presence could be the stimulus that causes the chronic inflammatory response in the chronic course of this CD. In the case of single location, the treatment of choice is surgical removal.
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